GlassScriptPhysician profile
David M Benderson
NPI 1568597334
$3,631.07
in general payments reported to CMS, 2019-2025
22 companies · $340 in 2025
The $340 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $206 · 2020: $228 · 2021: $382 · 2022: $546 · 2023: $338 · 2024: $1,591 · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,500 · Food and Beverage: $769.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,500.00 |
| Food and Beverage | $768.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $1,518.62 | 2024 | Xdemvy |
| Abbvie INC. | $465.22 | 2022-2025 | Durysta, Vuity, Lumigan |
| Allergan, INC. | $464.59 | 2019-2022 | |
| Alcon Vision LLC | $298.14 | 2020-2025 | Clareon, Rocklatan, Unity |
| Johnson & Johnson Surgical Vision, INC. | $215.24 | 2019-2025 | Tecnis Iol, Veritas Vision System |
| Biotissue Holdings INC. | $140.47 | 2021-2022 | |
| Aerie Pharmaceuticals, INC. | $97.52 | 2020-2021 | |
| Sight Sciences, INC. | $53.78 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
| Oyster Point Pharma, INC. | $52.29 | 2022-2023 | Tyrvaya |
| Kala Pharmaceuticals, INC. | $43.78 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $41.19 | 2019-2023 | |
| Harrow Eye, LLC | $36.30 | 2024-2025 | Vevye |
| New World Medical,INC. | $33.83 | 2024 | Kahook Dual Blade, Ahmed Glaucoma Valve, Clearpath |
| Sun Pharmaceutical Industries INC. | $30.51 | 2021-2022 | |
| Johnson & Johnson Vision Care, INC. | $28.91 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beaver-Visitec International, INC. | $19.07 | 2021 | |
| Rxsight INC | $17.63 | 2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Ocular Therapeutix, INC. | $16.49 | 2025 | Dextenza |
| Bausch & Lomb Americas INC. | $16.38 | 2023 | Vyzulta |
| Mallinckrodt Hospital Products INC. | $14.86 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.13 | 2019 | |
| Glaxosmithkline, LLC. | $12.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Benderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.